Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Costco Wholesale Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Costco Wholesale Corporation trades at $941.23 (market cap $422.52B). The key difference: Costco Wholesale Corporation is far larger — about 83.5× ACADIA Pharmaceuticals Inc.'s market cap, and Costco Wholesale Corporation pays a 0.62% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | COST | |
|---|---|---|
Market Cap | $5.06B | $422.52B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $1.09K |
52-Week Low | $20.06 | $849.63 |
Enterprise Value | $4.18B | $410.66B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Costco (COST) trades at $952.75, up 0.52% with a neutral technical outlook. The stock shows strong fundamentals with revenue growth from $254.5B in 2024 to $275.2B in 2025 and net income reaching $8.1B. Recent March sales surged 11.3% year-over-year to $28.41B. Valuation metrics remain elevated with P/E at 47.93 and P/S at 1.44. Analyst consensus is strongly bullish with 65.5% buy ratings and a $1,120 price target.
The investment case centers on Costco's membership-driven profit engine and consistent execution, though high valuation presents near-term risk. Upside potential exists if the company maintains its premium growth trajectory, while any earnings disappointment could trigger valuation compression. The recent membership fee increase and strong renewal rates support margin expansion prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
